The platform built to cut CAR-T manufacturing costs by ~50% is about to power its first patient dosing.
When Onyx caught up with CEO Fabian Gerlinghaus at JPM 2026, we'd just heard groundbreaking news.
Cabaletta Bio’s investigational CAR T cell therapy 'rese-cel' had received FDA clearance of an IND Amendment to use Cellares’ Cell Shuttle platform for manufacturing.
The biotech industry destroys billions in shareholder value every year - failed trials, depleted cash, and abandoned pipelines leaving investors with nothing.
90% of oncology drugs fail in clinical trials - costing billions and, more importantly, delaying life-saving treatments for patients who need them now.
Will large pharma's AI adoption and deployment to drug development redefine biotech's role and business model?
38 trillion bacteria live in your gut — yet most microbiome tests can only identify them at the genus level, missing the strains that actually matter.
